Eltek Secures $2.4 Million Defense Contract for 2026-2027 Deliveries

Zimmer Biomet announced that management team members will present at the Annual Morgan Stanley Healthcare Conference on September 8, 2025. A live webcast of the presentation will be available on Zimmer Biomet's Investor Relations website. The company is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health.

Zimmer Biomet (NYSE:ZBH), a leading global medical technology company, has announced that its management team will deliver a presentation at the upcoming Annual Morgan Stanley Healthcare Conference. The event is scheduled for Monday, September 8, 2025, at 8:30 a.m. ET. Investors can access the live webcast through Zimmer Biomet's Investor Relations website, where the presentation will also be available for replay after the conference concludes.

Zimmer Biomet's comprehensive portfolio is designed to maximize mobility and improve health, with a focus on orthopedic solutions. The company has been making significant strides in the orthopedic market, with recent financial results reflecting its resilience and growth strategies.

In the second quarter of 2025, Zimmer Biomet reported $2.08 billion in sales and an operating margin of nearly $300 million, surpassing revenue expectations but falling short of earnings per share (EPS) targets. The company's U.S. hips and knees franchises performed exceptionally well, reinforcing its dominance in core reconstructive markets [2].

Zimmer Biomet's Chairman, President, and CEO Ivan Tornos highlighted the company's ability to navigate market headwinds and international delays, achieving 2.8% organic growth despite these challenges. The company raised its full-year organic revenue growth outlook to 3.5%–4.5% (excluding Paragon 28) and nudged up EPS guidance to $8.10–$8.30, citing stronger operational efficiency and less tariff drag than expected.

One of the key highlights of the presentation is expected to be the pending acquisition of Monogram Technologies, a maker of the first robot to complete a fully autonomous surgery using Monogram implants. This acquisition is a significant move for Zimmer Biomet, positioning it as a leader in surgical ecosystems, including ASCs (Ambulatory Surgical Centers), robotics, and advanced digital tools.

The company's CFO, Suketu Upadhyay, emphasized continued investment in ASCs and robotics, noting that early adoption of recent launches and commercial expansion sets the stage for "second half acceleration." Despite acknowledging room for improvement, Upadhyay underscored Zimmer Biomet's focus on high-growth segments where orthopedic procedure volumes and margins are expanding fastest.

Zimmer Biomet's presentation at the Annual Morgan Stanley Healthcare Conference is an opportunity for investors and financial professionals to gain insights into the company's strategies, financial performance, and future prospects. The live webcast will provide a platform for the company to share its vision and plans, offering valuable information for those interested in the medical technology sector.

References:
[1] https://www.stocktitan.net/news/ZBH/zimmer-biomet-to-present-at-the-annual-morgan-stanley-healthcare-xy3uv4s2231i.html
[2] https://ryortho.com/2025/08/zimmer-biomet-delivers-solid-q2-all-eyes-on-robotics-and-monogram/